Prot# MGL-3196-11: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic

Project: Research project

Project Details

StatusActive
Effective start/end date12/20/19 → 12/31/27

Funding

  • Pharmaceutical Research Associates, Inc. (Prot# MGL-3196-11 // Prot# MGL-3196-11)
  • Synta Pharmaceuticals Corp. (Prot# MGL-3196-11 // Prot# MGL-3196-11)